Cargando...
Evaluating ibrutinib in the treatment of symptomatic Waldenstrom’s macroglobulinemia
Waldenstrom’s macroglobulinemia (WM) is a rare lymphoplasmacytic lymphoma with indolent course and prolonged disease course. The first-in-class Bruton’s tyrosine kinase inhibitor, ibrutinib, has shown significant activity and a distinct adverse event profile among both newly diagnosed and relapsed/r...
Gardado en:
| Publicado en: | J Blood Med |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Dove
2019
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6717707/ https://ncbi.nlm.nih.gov/pubmed/31695539 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/JBM.S183997 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|